Back to School: How biopharma can reboot drug development. Access exclusive analysis here
NOV said that in an open-label Phase II trial, 15 of 61 evaluable patients with hormone resistant prostate cancer (HRPC) who
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury